JP2013532130A5 - - Google Patents

Download PDF

Info

Publication number
JP2013532130A5
JP2013532130A5 JP2013510364A JP2013510364A JP2013532130A5 JP 2013532130 A5 JP2013532130 A5 JP 2013532130A5 JP 2013510364 A JP2013510364 A JP 2013510364A JP 2013510364 A JP2013510364 A JP 2013510364A JP 2013532130 A5 JP2013532130 A5 JP 2013532130A5
Authority
JP
Japan
Prior art keywords
represented
compound
pharmaceutically acceptable
acceptable salt
structural formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013510364A
Other languages
Japanese (ja)
Other versions
JP5715241B2 (en
JP2013532130A (en
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/036701 external-priority patent/WO2011143669A2/en
Publication of JP2013532130A publication Critical patent/JP2013532130A/en
Publication of JP2013532130A5 publication Critical patent/JP2013532130A5/ja
Application granted granted Critical
Publication of JP5715241B2 publication Critical patent/JP5715241B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (5)

Figure 2013532130

からなる群より選択される構造式で表される化合物、またはその薬学的に許容され得る塩。
Figure 2013532130

A compound represented by a structural formula selected from the group consisting of: or a pharmaceutically acceptable salt thereof.
構造式
Figure 2013532130

で表される請求項1に記載の化合物、またはその薬学的に許容され得る塩。
Structural formula
Figure 2013532130

The compound of Claim 1 represented by these, or its pharmaceutically acceptable salt.
構造式
Figure 2013532130

で表される請求項1に記載の化合物、またはその薬学的に許容され得る塩。
Structural formula
Figure 2013532130

The compound of Claim 1 represented by these, or its pharmaceutically acceptable salt.
構造式
Figure 2013532130

で表される請求項2に記載の化合物、またはその薬学的に許容され得る塩。
Structural formula
Figure 2013532130

The compound of Claim 2 represented by these, or its pharmaceutically acceptable salt.
構造式
Figure 2013532130

で表される請求項3に記載の化合物、またはその薬学的に許容され得る塩。
Structural formula
Figure 2013532130

The compound of Claim 3 represented by these, or its pharmaceutically acceptable salt.
JP2013510364A 2010-05-14 2011-05-16 Compositions and methods for treating neoplasms, inflammatory diseases, and other disorders Active JP5715241B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US33499110P 2010-05-14 2010-05-14
US61/334,991 2010-05-14
US37074510P 2010-08-04 2010-08-04
US61/370,745 2010-08-04
US37586310P 2010-08-22 2010-08-22
US61/375,863 2010-08-22
PCT/US2011/036701 WO2011143669A2 (en) 2010-05-14 2011-05-16 Compositions and methods for treating neoplasia, inflammatory disease and other disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015049960A Division JP5937247B2 (en) 2010-05-14 2015-03-12 Compositions and methods for treating neoplasms, inflammatory diseases, and other disorders

Publications (3)

Publication Number Publication Date
JP2013532130A JP2013532130A (en) 2013-08-15
JP2013532130A5 true JP2013532130A5 (en) 2014-11-06
JP5715241B2 JP5715241B2 (en) 2015-05-07

Family

ID=49052897

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013510364A Active JP5715241B2 (en) 2010-05-14 2011-05-16 Compositions and methods for treating neoplasms, inflammatory diseases, and other disorders
JP2015049960A Active JP5937247B2 (en) 2010-05-14 2015-03-12 Compositions and methods for treating neoplasms, inflammatory diseases, and other disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015049960A Active JP5937247B2 (en) 2010-05-14 2015-03-12 Compositions and methods for treating neoplasms, inflammatory diseases, and other disorders

Country Status (1)

Country Link
JP (2) JP5715241B2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5913292B2 (en) * 2010-05-14 2016-04-27 ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド Compositions and methods for modulating metabolism
PT2571503E (en) 2010-05-14 2015-04-29 Dana Farber Cancer Inst Inc Compositions and their use in treating neoplasia, inflammatory disease and other disorders
CN105050605A (en) * 2012-06-25 2015-11-11 翁科埃蒂克斯股份公司 Method of treating lymphoma using thienotriazolodiazepine compounds
EP3030242A1 (en) * 2013-08-06 2016-06-15 Oncoethix GmbH Method of treating diffuse large b-cell lymphoma (dlbcl) using a bet-bromodomain inhibitor
WO2015070020A2 (en) 2013-11-08 2015-05-14 Dana-Farber Cancer Institute, Inc. Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
MX2016011160A (en) 2014-02-28 2017-04-27 Tensha Therapeutics Inc Treatment of conditions associated with hyperinsulinaemia.
CN107787227A (en) * 2015-06-26 2018-03-09 腾沙治疗公司 The treatment of NUT center line cancers
JP2018526421A (en) * 2015-09-11 2018-09-13 ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド Cyanothienotriazolodiazepines and their use
SG10202007099TA (en) * 2015-09-11 2020-08-28 Dana Farber Cancer Inst Inc Acetamide thienotriazoldiazepines and uses thereof
CA2999523A1 (en) * 2015-10-02 2017-04-06 Dana-Farber Cancer Institute, Inc. Combination therapy of bromodomain inhibitors and checkpoint blockade
AU2017219627B2 (en) * 2016-02-15 2021-08-05 The Regents Of The University Of Michigan Fused 1,4-oxazepines and related analogs as BET bromodomain inhibitors
MX2019006956A (en) * 2016-12-16 2019-08-01 Hoffmann La Roche Process for the manufacture of diazepine derivatives.
CN109503618A (en) * 2017-09-14 2019-03-22 成都海创药业有限公司 A kind of BRD4 inhibitor
WO2019238557A1 (en) * 2018-06-13 2019-12-19 Dybly Ag Preparation of condensed triazepine derivatives and their use as bet inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1227555A (en) * 1996-06-12 1999-09-01 日本烟草产业株式会社 Cytokine production inhibitors triazepine compounds, and intermediates thereof
US7589167B2 (en) * 2000-02-22 2009-09-15 J. David Gladstone Institutes ZA loops of bromodomains
AU2004215359A1 (en) * 2003-02-27 2004-09-10 Abbott Laboratories Heterocyclic kinase inhibitors
CA2710740C (en) * 2007-12-28 2016-07-19 Shinji Miyoshi Thienotriazolodiazepine compound as antitumor agent
KR20120097508A (en) * 2009-11-05 2012-09-04 글락소스미스클라인 엘엘씨 Benzodiazepine bromodomain inhibitor

Similar Documents

Publication Publication Date Title
JP2013532130A5 (en)
JP2011105738A5 (en)
JP2012107057A5 (en)
JP2012111758A5 (en)
JP2009149903A5 (en)
JP2019194236A5 (en)
JP2011518833A5 (en)
JP2011168603A5 (en)
JP2012081521A5 (en)
JP2011510079A5 (en)
JP2013032389A5 (en)
JP2014221779A5 (en)
JP2009535462A5 (en)
JP2012255926A5 (en)
JP2015522045A5 (en)
JP2011520976A5 (en)
JP2013173781A5 (en)
JP2013541578A5 (en)
JP2011519871A5 (en)
JP2010529196A5 (en)
JP2011170856A5 (en)
JP2018521020A5 (en)
JP2012094862A5 (en)
JP2013532687A5 (en)
JP2011037885A5 (en)